Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DM1237M)

Drug Name	Alfacalcidol DM1237M
Synonyms	Alfacalcidol [INN:BAN:JAN]; Alfacalcidolum; Alfacalcidolum [INN-Latin]; Alfarol; Alpha D 3; Alphacalcidol; Alsiodol; Bondiol; EinsAlpha; One-Alpha; Oxydevit; Sinovul; URQ2517572; Un-Alpha; Vitamin D3, 1alpha-Hydroxy-; alfacalcidol; alpha-Calcidol; (5Z,7E)-9,10-Seco-5,7,10(19)-cholestatrien-1alpha,3beta-diol; 1-Hydroxycholecalciferol; 1-Hydroxyvitamin D3; 1alpha-Hydroxy-vitamin D3; 1alpha-Hydroxycholecalciferol; 1alpha-Hydroxyvitamin D3; 1alpha-OH-D3; 41294-56-8; CCRIS 3341; CHEBI:31186; UNII-URQ2517572
Structure
Structure	3D MOL			2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

3 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Renal osteodystrophy	DISN2OO5	N.A.	Approved	[1]
Hypoparathyroidism	DISICS0V	5A50	Approved	[2]
Hyperparathyroidism	DIS4FVAT	5A51	Approved	[3]
------------------------------------------------------------------------------------

References

1	Cross-linked C-terminal telopeptide of type I collagen in serum before and after treatment with alfacalcidol and calcium carbonate in early and moderate chronic renal failure. Nephron. 2002 Oct;92(2):304-8.
2	Auditing the Efficacy and Safety of Alfacalcidol and Calcium Therapy in Idiopathic Hypoparathyroidism. J Clin Endocrinol Metab. 2019 Apr 1;104(4):1325-1335.
3	X-Linked Hypophosphatemia. 2012 Feb 9 [updated 2023 Dec 14]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews(?) [Internet]. Seattle (WA): University of Washington, Seattle; 1993C2024.